Monday, May 10, 2021 |
Baltimore
57°
Cloudy
FOLLOW US:

Emergent faces lawsuit, congressional scrutiny over COVID vaccine production troubles

April 21, 2021

The Maryland company that recently had to pause COVID-19 vaccine production over quality issues in its Baltimore plant now also faces a shareholder lawsuit and a congressional investigation for its behavior during the pandemic. An institutional shareholder filed a lawsuit Monday in U.S. District Court for Maryland that seeks class-action status for what it alleges were false statements by Emergent BioSolutions and some of the Gaithersburg-based company’s executives about its readiness to mass-produce vaccine.

Article Source: Baltimore Sun

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.